CHME: AI 评分 52/100 — AI 分析 (4月 2026)

China Medicine Corporation produces and distributes a range of pharmaceutical products in China, including prescription and over-the-counter drugs, traditional Chinese medicines, and medical devices. The company focuses on providing healthcare solutions for various conditions, leveraging its distribution network across China.

Key Facts: AI Score: 52/100 Sector: Healthcare

公司概况

概要：

China Medicine Corporation distributes pharmaceutical products including prescription drugs, OTC medicines, traditional Chinese remedies, and medical devices within China. Operating in the healthcare sector, the company leverages a domestic sales network to reach diverse markets and address various medical needs, reflected in its modest profit margin.

CHME是做什么的？

China Medicine Corporation, established in 2005 and based in Guangzhou, China, is involved in the production and distribution of a wide array of pharmaceutical and healthcare products. Originally named Lounsberry Holdings III, Inc., the company rebranded in May 2006 to reflect its focus on the Chinese medicine market. The company's product portfolio includes prescription and over-the-counter (OTC) drugs, traditional Chinese medicine products, herbs, dietary supplements, medical devices, and medical formulations. These products cater to various therapeutic applications, including oncology, hypertension, and detoxification. Specific product lines address conditions such as stagnation of heart blood, upper respiratory infections, hepatitis, menstrual irregularities, anemia, and cerebrovascular diseases. China Medicine Corporation distributes its products through a sales network that spans across China, ensuring broad market coverage. The company's operations are primarily concentrated within the Chinese domestic market, focusing on meeting the healthcare needs of the local population through a combination of modern and traditional medical solutions. With a workforce of 281 employees, China Medicine Corporation aims to maintain a competitive edge through its diverse product offerings and established distribution channels.

CHME的投资论点是什么？

China Medicine Corporation presents a mixed investment profile. The company's distribution network within China provides access to a large and growing market for both prescription and traditional medicines. With a P/E ratio of 0.09, the company appears undervalued, but this must be weighed against the company's OTC status and high beta of 11.80, indicating high volatility. A profit margin of 2.7% and gross margin of 29.3% suggest potential for improved efficiency. Growth catalysts include expanding its product lines and penetrating deeper into existing markets. However, the lack of dividend payments may deter some investors. Investors should closely monitor the company's ability to navigate regulatory challenges and competitive pressures within the Chinese pharmaceutical market.

CHME在哪个行业运营？

China Medicine Corporation operates within the competitive pharmaceutical distribution industry in China. The Chinese pharmaceutical market is characterized by increasing demand for both modern and traditional medicines, driven by an aging population and rising healthcare awareness. The industry is also subject to stringent regulatory oversight and pricing pressures. China Medicine competes with other distributors and manufacturers, including both domestic and international players. The company's focus on traditional Chinese medicine provides a niche market, but it must also navigate competition from companies with broader product portfolios and stronger financial resources. The market is growing, but success depends on regulatory compliance, efficient distribution, and product innovation.

Medical - Distribution

Healthcare

CHME有哪些增长机遇？

Expanding product lines to include more innovative and higher-margin products represents a significant growth opportunity. The company can invest in research and development or strategic partnerships to introduce new drugs and medical devices that address unmet medical needs in the Chinese market. The market for innovative pharmaceuticals in China is projected to grow at a rate of 10-15% annually, offering substantial revenue potential. This expansion can be realized within the next 3-5 years with adequate investment and regulatory approvals.
Deepening market penetration in existing geographic regions can drive revenue growth. By strengthening its distribution network and enhancing its sales and marketing efforts, China Medicine Corporation can increase its market share in key provinces and cities. The company can also target underserved rural areas with affordable healthcare solutions. The potential market size for pharmaceuticals in rural China is estimated to be $50 billion, providing a significant growth opportunity over the next 2-4 years.
Leveraging e-commerce platforms to reach a wider customer base is another growth avenue. China's e-commerce market is booming, and online sales of pharmaceuticals are increasing rapidly. By establishing a strong online presence and offering convenient online ordering and delivery services, China Medicine Corporation can tap into this growing market segment. The online pharmaceutical market in China is expected to reach $30 billion by 2028, offering a substantial growth opportunity over the next 1-3 years.
Strategic acquisitions of smaller pharmaceutical companies or distributors can accelerate growth and expand market reach. By acquiring companies with complementary product portfolios or established distribution networks, China Medicine Corporation can strengthen its competitive position and gain access to new markets and customers. The market for pharmaceutical acquisitions in China is active, with numerous opportunities for consolidation. Strategic acquisitions can be pursued over the next 2-5 years.
Increasing focus on traditional Chinese medicine (TCM) products can capitalize on the growing demand for natural and holistic healthcare solutions. China Medicine Corporation can invest in the development and marketing of high-quality TCM products that are backed by scientific research and clinical evidence. The market for TCM products in China is estimated to be $40 billion, offering a significant growth opportunity. This focus can be implemented within the next 1-3 years.

P/E ratio of 0.09 suggests potential undervaluation compared to industry peers.
Gross margin of 29.3% reflects the company's ability to manage production and distribution costs.
Profit margin of 2.7% indicates room for improvement in operational efficiency.
Beta of 11.80 signifies high volatility compared to the broader market.
The company distributes products through a sales network in China, providing access to a large and growing market.

CHME提供哪些产品和服务？

Produces prescription drugs for various medical conditions.
Distributes over-the-counter (OTC) medicines.
Offers traditional Chinese medicine (TCM) products.
Provides herbs and dietary supplements.
Supplies medical devices.
Develops medical formulations.

CHME如何赚钱？

Manufactures and sources pharmaceutical products.
Distributes products through a sales network in China.
Generates revenue through the sale of prescription drugs, OTC medicines, TCM products, and medical devices.
Focuses on both modern and traditional healthcare solutions.

Hospitals and clinics.
Pharmacies and drug stores.
Individual consumers seeking healthcare products.
Healthcare providers prescribing medications.

Established distribution network in China.
Diverse product portfolio of both modern and traditional medicines.
Brand recognition within the Chinese market.
Relationships with healthcare providers and pharmacies.

什么因素可能推动CHME股价上涨？

Upcoming: Potential regulatory approvals for new pharmaceutical products could drive revenue growth.
Ongoing: Expansion of the company's distribution network in China can increase market reach.
Ongoing: Increasing demand for traditional Chinese medicine products may boost sales.
Upcoming: Strategic partnerships with other healthcare companies could enhance product offerings.

CHME的主要风险是什么？

Potential: Stringent regulatory oversight and pricing pressures in the Chinese pharmaceutical market could impact profitability.
Potential: Competition from domestic and international players may erode market share.
Ongoing: The company's reliance on the Chinese market exposes it to economic and political risks.
Potential: Counterfeit products could damage the company's reputation.
Ongoing: High beta indicates high volatility, which could lead to significant price fluctuations.

CHME的核心优势是什么？

Established distribution network in China.
Diverse product portfolio.
Focus on both modern and traditional medicines.
Brand recognition in the Chinese market.

CHME的劣势是什么？

Low profit margin.
High beta indicating high volatility.
Reliance on the Chinese market.
OTC market listing.

CHME有哪些机遇？

Expanding product lines with innovative drugs.
Deepening market penetration in existing regions.
Leveraging e-commerce platforms.
Strategic acquisitions of smaller companies.

CHME面临哪些威胁？

Stringent regulatory oversight.
Pricing pressures in the pharmaceutical market.
Competition from domestic and international players.
Potential for counterfeit products.

CHME的竞争对手是谁？

China Yida Holding Co Ltd — Focuses on pharmaceutical distribution and retail. — (CHYPF)
Conatus Pharmaceuticals Inc — Develops and commercializes novel medicines. — (CTTH)
Datarock Exploration Inc — Operates in the resource exploration sector. — (DTRK)
Ensign Energy Services Inc — Provides oilfield services. — (EPGNF)
Ovation Science Inc — Develops topical and transdermal cannabis products. — (OVATF)

Key Metrics

MoonshotScore: 52/100

Company Profile

CEO: Senshan Yang
Headquarters: Guangzhou, CN
Employees: 281
Founded: 2006

AI Insight

AI analysis pending for CHME

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does China Medicine Corporation do?

China Medicine Corporation is a pharmaceutical company that produces and distributes a wide range of healthcare products in China. Its portfolio includes prescription drugs, over-the-counter medicines, traditional Chinese medicine products, herbs, dietary supplements, and medical devices. The company operates through a distribution network across China, serving hospitals, clinics, pharmacies, and individual consumers. China Medicine Corporation aims to provide both modern and traditional healthcare solutions to meet the diverse needs of the Chinese market.

What do analysts say about CHME stock?

Analyst coverage of China Medicine Corporation (CHME) is limited due to its OTC listing and smaller market capitalization. Key valuation metrics such as the P/E ratio of 0.09 suggest potential undervaluation, but this should be considered in light of the company's higher risk profile. Growth considerations include the company's ability to expand its product lines, penetrate deeper into existing markets, and leverage e-commerce platforms. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.

What are the main risks for CHME?

China Medicine Corporation faces several risks, including stringent regulatory oversight and pricing pressures in the Chinese pharmaceutical market. Competition from domestic and international players could erode market share. The company's reliance on the Chinese market exposes it to economic and political risks. The potential for counterfeit products could damage the company's reputation. Additionally, the company's high beta indicates high volatility, which could lead to significant price fluctuations. The OTC listing also carries additional risks related to liquidity and disclosure.